1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

300760.SZ
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.CN flagShenzhen Stock Exchange
138.17
CNY
-2.43
- -
167.52BMarket Cap
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
300760.SZ
(Shenzhen Stock Exchange)

Recent

price

138.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.47
8.63
9.09
10.23
12.35
13.62
17.3
20.8
25.1
28.83
30.33
27.47
20.06
Revenue per Share
1.47
0.98
1.61
2.37
3.34
3.85
5.48
6.59
7.94
9.56
9.64
6.71
4.4
Basic EPS, GAAP
-0.64
1.54
2.64
2.59
3.01
3.25
6.32
6.25
8.45
6.91
8.65
6.69
-1.35
Free Cash Flow per Basic Share
0.05
3.69
6.56
0.56
0.85
1
1.5
2.5
3.5
8.81
7.22
4.63
3.32
Dividend per Share
9.06
6.36
1.4
3.19
5.7
8.07
12.04
16.14
20.64
21.37
23.81
25.88
27.8
Book Value per Share
7.75
4.67
2.29
4.01
11.45
13.33
17.07
16.92
20.93
21.22
18.65
20.58
22.39
Tangible Book Value per Share
925
928
994
1,092
1,114
1,216
1,216
1,215
1,210
1,212
1,211
1,212
1,212
Basic Weighted Avg Shares
7,836
8,013
9,032
11,174
13,753
16,556
21,026
25,270
30,366
34,932
36,726
33,282
24,306
Sales/Revenue/Turnover
14.34
12.14
16.85
29.33
30.37
31.03
35.86
35.98
35.13
36.98
35.53
29.86
27.22
Operating Margin (%)
- -
316
285
304
331
394
472
700
885
1,010
1,469
1,721
- -
Depreciation Expense
1,360
910
1,600
2,589
3,719
4,681
6,658
8,002
9,607
11,582
11,668
8,136
5,336
Net Income, GAAP
4.21
13.68
12.93
11.26
12.09
12.73
10.47
11.23
12.26
11.01
9.83
12.64
9.26
Effective Tax Rate (%)
17.35
11.35
17.72
23.17
27.04
28.27
31.66
31.66
31.64
33.16
31.77
24.44
21.95
Profit Margin (%)
6,019
1,959
1,735
2,355
10,662
13,505
13,328
12,706
18,836
16,773
15,219
15,811
16,309
Working Capital
1,202
311
1,678
- -
- -
- -
122
152
139
182
178
225
210
LT Debt
9,662
6,538
4,601
6,654
15,167
18,607
23,290
26,968
31,999
33,346
40,758
43,011
44,846
Total Equity
- -
8.42
15.72
34.49
30.5
26.16
31.76
31.46
31.05
34.5
31.48
20.74
13.36
Return on Invested Capital (%)
- -
10.01
25.39
51.06
63.94
57.73
53.97
46.16
42.65
44.89
38.41
22.2
13.48
Return on Capital (%)
- -
12.73
43.84
106.22
75.66
57.94
54.47
46.74
43.11
45.54
42.64
27.03
16.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
124
133
LT Borrowings
- -
4
- -
LT Finance Leases
- -
221
210
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,212
1,212
Market Capitalization
297,638
230,719
199,533

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
27,410
28,054
Cash, Cash Equivalents & STI
- -
17,941
18,089
Accounts Receivable, Net
- -
3,408
3,574
Inventories
- -
5,004
5,254
Total Current Liabilities
- -
11,600
11,745
Payables & Accruals
- -
- -
- -
ST Debt
- -
124
133
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.72%
13.28%
5.53%
Free Cash Flow
24.04%
3.56%
-22.59%
Net Income, GAAP
28.07%
6.26%
-30.28%
Sales/Revenue/Turnover
15.8%
10.23%
-9.38%
Total Cash Common Dividend
33.72%
40.83%
-35.78%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,373
11,158
8,954
7,241
36,726
2025
8,237
8,506
- -
7,448
33,282
2026
8,352
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.61
- -
- -
- -
9.64
2025
2.17
- -
- -
- -
6.71
2026
1.92
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
7.22
2025
- -
- -
- -
- -
4.63
2026
- -
- -
- -
- -
- -
Similar Companies
Venus Concept Inc. (VERO)
Bio-Rad Laboratories, Inc. (BIO)
Nuwellis, Inc. (NUWE)
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
DIH Holding US, Inc. Warrants (DHAIW)
Scandinavian Medical Solutions A/S (SMSMED.CO)
Business
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. engages in the development, manufacturing, and marketing of advanced medical devices and solutions. The company operates primarily through three core business segments: Patient Monitoring and Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems. Its product portfolio includes patient monitors, biotelemetry systems, anesthesia delivery systems, defibrillators, electrocardiography (ECG) machines, pulse oximeters, hospital beds, ultrasound systems, hematology analyzers, biochemistry analyzers, reagents, ventilators, and digital laboratory solutions. Mindray serves hospitals, clinics, and diagnostic laboratories globally with a robust presence across major international markets. Founded in 1991 and headquartered in Shenzhen, China, the company has expanded through strategic acquisitions and technological innovation. In recent years, Mindray has made significant advances including the launch of Project 2030 aimed at advancing women's health ultrasound technology with new products such as the Nuewa R9 Platinum featuring 4D super-resolution imaging and broadening global ultrasound education. The company also developed a highly sensitive hs-cTnI cardiac biomarker assay improving myocardial injury diagnostics. A major strategic move in 2024 was Mindray's $927 million acquisition to gain control of APT Medical, a specialized cardiovascular medical device firm, enhancing its capabilities and market penetration in cardiovascular technologies and consumables. Additionally, Mindray has established a strategic cooperation with Inpeco to augment laboratory automation solutions. These developments reflect Mindray's focus on expanding its product offerings, strengthening its global market presence, and enhancing integrated solutions in patient monitoring, diagnostics, and imaging technologies.